Insider buying last 90 days
No open-market insider purchases were filed for AZN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AZN insider filing, plotted on the chart in Gekko.Open AZN in Gekko
NYSE: AZN
AstraZeneca (AZN) Stock Analysis & Forecast
Nov 4 close
$189.01+5.13 (+2.8%)
Gekko Brief
AI summaryNov 4 closeThis week AstraZeneca disclosed a roughly $10 billion offer for Rhythm Pharmaceuticals, a move that would expand its rare disease portfolio. RBC Capital Markets analyst Trung Huynh maintained an Outperform rating and raised his price target from $195.27 to $204.18 following the company's third-quarter results, which showed 9-month 2026 total revenue growth of 7% and core EPS growth of 14%, with oncology, rare disease, and R&I all posting double-digit growth. Separately, AstraZeneca terminated a Phase III trial for Ultomiris in delayed graft function due to a low probability of meeting its primary efficacy endpoint, and the company also outlined a $2 billion restructuring initiative through 2029.
AZN closed at $189.01, up 2.8%, sitting above both its 50-day average of $165.62 and 200-day average of $180.04, with one-month returns of 19.2% and three-month returns of 17.3%. The GekkoIndex reads 41.3, placing the stock in the Distribution zone, down 12.6 over five days. Gap to Gekko Fair Value of $286.96 stands at -34.1%.
The next earnings date falls on 9 February 2027, outside a typical 20-trading-day holding window; the last report on 30 October showed EPS of $2.79 against a $2.6 estimate, with a 7% reaction. One billionaire holder is noted, though no insider, Congress, or options activity appears in their respective windows. Seasonality over the next 20 trading days has averaged 0.6% across 5 years, rising in 3 of them. The consensus target stands at $206.66, implying 9.3% upside.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
AstraZeneca price vs fair value
Close $189.01200-day averageGekko Fair Value $286.96
AstraZeneca quick facts
- Market cap
- $293.1B
- P/E ratio
- 26.4
- Forward P/E
- 16.3
- EPS, TTM
- $7.07
- Revenue, TTM
- $62.38B
- Profit margin
- 17.7%
- Dividend yield
- 1.73%
- Beta
- 0.17
- Volume
- 4.47M avg 3.17M
- 1-year return
- +9.7%
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±4.8%
- 50-day average
- $165.62
- 200-day average
- $180.04
- Next earnings
- Feb 9 before open
- Shares outstanding
- 1.55B
AstraZeneca swing-trade checklist
AstraZeneca scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $189.01 sits between the 50-day ($165.62) and 200-day ($180.04) averages, or the averages disagree.
See the chart - GekkoIndexheadwind
41.3, Distribution
Reading 41.3 is in the Distribution zone.
See the GekkoIndex - Fair valuesupportive
34.1% below
Price is 34.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 96 days
Next report Feb 9, 2027, 96 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.6% on average
From this point in the calendar, the next 20 trading days averaged +0.6% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
AstraZeneca stock chart and price history
AstraZeneca closed at $189.01 on Nov 4, 2026, +9.7% over the past year, inside a 52-week range of $153.41 to $212.71.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +19.2%
- 3 months
- +17.3%
- 6 months
- +2.2%
- 1 year
- +9.7%
The full AZN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AZN in Gekko
Follow AstraZeneca through every session
Put AZN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AZN in GekkoFree for 7 days. No credit card required.
About AstraZeneca
AstraZeneca is a biopharmaceutical company that takes medicines from early-stage research all the way to manufacturing and sale. Its drug lineup covers heart, kidney and metabolic disorders as well as cancer treatment, featuring names such as Tagrisso, Farxiga and Symbicort. The company also supplies products tied to COVID-19 and to rare medical conditions, among them Vaxzevria and Soliris.
Sales reach both general practitioners and specialists, carried out through teams of representatives and local offices spread across Britain, mainland Europe, the Americas, Asia, Africa and Australasia. Beyond its own labs, AstraZeneca teams up with outside groups on new science, working alongside Neurimmune on an antibody treatment, BenevolentAI on lupus research, Lunit on AI tools for reading lung cancer scans, and Absci on machine-learning methods for spotting oncology drug targets.
The business dates back to 1992, when it was formed as Zeneca Group PLC, before adopting the AstraZeneca name in April 1999. It runs its operations from Cambridge in the United Kingdom, and its stock trades on the NYSE under the ticker AZN.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- astrazeneca.com
AstraZeneca GekkoIndex: the smart money zone
AstraZeneca’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 41.3, in the Distribution zone, down 12.6 points over five sessions.
41.3Distribution
Down 12.6 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 25 | +1.3% | +3.2% | ||
| Accumulation | 171 | +0.7% | +0.8% | ||
| Neutral | 353 | +0.1% | +1.2% | ||
| Distribution (current zone) | 11 | −1.3% | +2.2% | ||
| Selling | 2 | Too few readings yet | |||
Average AZN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the AZN price, zone by zone.Track AZN in Gekko
Is AstraZeneca stock overvalued? Gekko Fair Value
AstraZeneca trades 34.1% below Gekko Fair Value of $286.96, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what AstraZeneca shares are worth, recalculated every trading day.
$286.96
Gekko Fair Value, Nov 4, 2026
34.1% Undervalued
At the end of Sep 2026 the price was 40.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open AZN in Gekko
AstraZeneca insider and Congress trading
No open-market insider purchases were filed for AstraZeneca, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AZN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AZN, plotted on the chart in Gekko.Open AZN in Gekko
Buybacks
AstraZeneca has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2026
- $103.7M
- As a share of market cap
- 0.04%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds AZN.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
AstraZeneca earnings: next date and track record
AstraZeneca reports on Feb 9, 2027, before the open (96 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Feb 9, 2027
Expected before the open, 96 days away
- EPS estimate
- $2.31
- Revenue estimate
- $16.59B
7 of 8reports beat the EPS estimate
±4.5%average move across the report
8 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 30, 2026 AI summary
- What they said
- AstraZeneca reported 9-month 2026 total revenue growth of 7% and core EPS growth of 14%. Excluding LOE headwinds from Farxiga and Brilinta, revenue grew 12%. Oncology, rare disease, and R&I all delivered double-digit growth. The company achieved 4 new medicine approvals and positive Phase III data from 12 programs, including tozorakimab, efzimfotase alfa, and sone-ve, representing over $10 billion in non-risk-adjusted peak sales potential.
- Guidance
- Management expressed increasing confidence in delivering their $80 billion revenue ambition by 2030. Pipeline readouts have de-risked key growth drivers, with efzimfotase alfa and sone-ve each potentially reaching $3-5 billion in peak sales. Sustainable long-term growth beyond 2030 is targeted.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 30, 2026 | $2.79 est $2.60 | $16.21B est $16.00B | +7.0% |
| Jul 27, 2026 | $2.63 est $2.50 | $15.38B est $15.44B | +1.9% |
| Apr 29, 2026 | $1.29 est $1.27 | $15.29B est $14.93B | +0.4% |
| Feb 10, 2026 | $2.12 est $2.09 | $15.50B est $15.44B | +8.9% |
| Nov 6, 2025 | $2.38 est $2.28 | $15.19B est $14.78B | +0.6% |
| Jul 29, 2025 | $2.18 est $2.18 | $14.46B est $14.10B | +6.0% |
| Apr 29, 2025 | $2.48 est $2.20 | $13.59B est $13.81B | +5.0% |
| Feb 6, 2025 | $2.10 est $2.07 | $14.89B est $14.23B | +6.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
AstraZeneca stock forecast and analyst price targets
Analysts’ average 12-month price target for AstraZeneca is $206.66, +9.3% from the last close.
$206.66consensus 12-month target, +9.3% from the last close
+2.2%average 20-day move after past Distribution readings
+0.6%average move over the next 20 trading days in the last 5 years
±2.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
AstraZeneca seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, AstraZeneca averaged +0.6% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.1% | 2 of 5 |
| Next 10 trading days | −2.0% | 3 of 5 |
| Next 15 trading days | +0.2% | 3 of 5 |
| Next 20 trading days | +0.6% | 3 of 5 |
| Next 30 trading days | +0.5% | 3 of 5 |
For scale, AZN’s typical 20-trading-day move in either direction is about 4.8%.
AstraZeneca market cap and key statistics
AstraZeneca’s market cap is $293.1B, with a P/E ratio of 26.4 and revenue of $62.38B over the last twelve months.
Valuation
- Market cap
- $293.1B
- P/E ratio
- 26.4
- Forward P/E
- 16.3
- EPS, TTM
- $7.07
- Gekko Fair Value
- $286.96
Trading
- Volume
- 4.47M
- Avg volume, 20 days
- 3.17M
- 52-week high
- $212.71
- 52-week low
- $153.41
- Shares outstanding
- 1.55B
Financials
- Revenue, TTM
- $62.38B
- Profit margin
- 17.7%
- Return on equity
- 22.6%
- Quarterly earnings growth, YoY
- +23.5%
Risk and income
- Beta
- 0.17
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±4.8%
- Dividend yield
- 1.73%
AstraZeneca stock news this week
Coverage of AstraZeneca this week reads positive: 4 positive, 2 neutral and 1 negative headlines.
- AstraZeneca Made $10 Billion Offer for Rhythm PharmaceuticalsWSJ, Nov 4
- AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar TimingBenzinga, Nov 3
- REG - AstraZeneca PLC - Admission of Further Securities to TradingTradingView, Nov 2
- 27,056 AstraZeneca Plc $AZN Shares Acquired by International Assets Investment Management LLCDefense World, Nov 2
- 1,929,102 Shares of AstraZeneca Plc $AZN Acquired by Bank Julius Baer & Co. Ltd ZurichDefense World, Nov 2
- AstraZeneca: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool, Nov 1
AstraZeneca peers
AstraZeneca’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Distribution | 27.7% above |
| JNJJohnson & Johnson | Neutral | 1.7% below |
| ABBVAbbVie | Neutral | 26.5% above |
| MRKMerck | Neutral | 8.6% below |
| PFEPfizer | Neutral | 4.1% below |
| VRTXVertex Pharmaceuticals | Neutral | 16.8% above |
A peer links to its own page where one exists.
AstraZeneca stock FAQ
What is AstraZeneca’s market cap?
AstraZeneca’s market cap is $293.1B at the Nov 4, 2026 close of $189.01, with 1.55B shares outstanding. The shares trade on a P/E ratio of 26.4.
What is the AstraZeneca stock forecast?
The consensus analyst 12-month price target for AstraZeneca is $206.66, +9.3% from the last close. Gekko doesn’t publish price predictions of its own.
Is AstraZeneca stock overvalued or undervalued?
On Gekko’s estimate AstraZeneca is undervalued: the Nov 4, 2026 close of $189.01 is 34.1% below Gekko Fair Value of $286.96. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does AstraZeneca report earnings next?
AstraZeneca is expected to report on Feb 9, 2027, before the market opens (96 days away). Analysts expect earnings of $2.31 per share on revenue of $16.59B. AstraZeneca beat the earnings estimate in 7 of its last 8 reports, moving 4.5% on average across the report.
What is AstraZeneca’s 52-week high and low?
AstraZeneca’s 52-week high is $212.71 and its 52-week low is $153.41; it closed at $189.01 on Nov 4, 2026, +9.7% over the past year.
Is AstraZeneca stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (fair value, earnings risk and seasonality), 1 as mixed (trend) and 1 as a headwind (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See AstraZeneca the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.